Omni unveils LeanPaws, a natural weight-management supplement for dogs

Omni, the UK-based pet nutrition company, has announced the forthcoming launch of LeanPaws, a natural supplement designed to help dogs manage weight safely and effectively. The product, which has been in development for more than two years, takes inspiration from human treatments like Ozempic but is formulated without drugs, instead relying on amino acids, probiotics, fibers and resistant starches to achieve similar effects.

Canine obesity has become a pressing issue, with recent figures suggesting that around one in two dogs are overweight. Excess weight can limit mobility, reduce quality of life and shorten lifespan, while also increasing the likelihood of chronic diseases and joint pain. Although exercise and dietary changes remain essential components of weight control, these are not always feasible, particularly for animals already suffering discomfort. Omni’s founders see LeanPaws as a way to provide dog owners with a practical, non-prescription option.

The company says LeanPaws is designed to be compatible with all types of diets, including fresh, wet, raw and high-fat formulations, and that it has minimal side effects compared to traditional pharmaceuticals. Its formulation is intended to support metabolism, regulate blood sugar and promote feelings of satiety. Resistant starches and dietary fibers are included to mimic the action of GLP-1, the hormone targeted by drugs such as Ozempic, while probiotics and prebiotics work to improve fat metabolism and gut health.

To validate the concept, Omni has conducted a blinded, placebo-controlled study in Norway involving veterinary professionals. Dog owners participating in the trial did not know whether their pets were given LeanPaws or a placebo, providing more objective outcomes. According to the company, nearly 80% of dogs in the study lost weight, with virtually no reported side effects. These results, coupled with improvements in satiety and reductions in body fat, are being prepared for publication in collaboration with Nottingham Vet School. Omni plans to present the findings at a major veterinary conference later this year.

Dr Guy Sandelowsky, Co-founder of Omni, described the mission behind the supplement as part of a broader commitment to canine wellbeing. The company’s aim, he said, is to give veterinarians and owners a tool that helps dogs live longer and healthier lives without relying on restrictive regimes or prescription medication. His fellow co-founder, Shiv Sivakumar, echoed that vision, stressing the importance of credible science in shaping new approaches to pet nutrition.

Interest in LeanPaws is already growing ahead of its scheduled 2026 launch. Omni reports early engagement from veterinary retailers and is considering a waitlist model similar to that used by high-end human supplement brands. The company believes such an approach could help manage demand while reinforcing the product’s positioning as a premium, evidence-based solution.

The development of LeanPaws reflects a wider trend of cross-pollination between human and animal health fields. The popularity of GLP-1 medications such as Ozempic and Wegovy has brought weight management to the forefront of medical and consumer conversations. While LeanPaws is not a pharmaceutical and does not contain semaglutide or similar compounds, its formulation is designed to tap into some of the same mechanisms in a natural way. By combining amino acids, prebiotics, probiotics and functional fibers, Omni is attempting to replicate the satiety and metabolic benefits that have made GLP-1 drugs so prominent.

Clinical validation will be crucial for market acceptance, particularly among veterinary professionals. Omni’s decision to partner with Nottingham Vet School and submit findings to a peer-reviewed journal suggests a deliberate strategy to build credibility. The company emphasizes that LeanPaws is intended to be recommended by veterinarians as part of a broader weight-management plan rather than a replacement for lifestyle interventions.

As part of its rollout, Omni is also positioning LeanPaws as allergy-friendly, acknowledging that many dog owners face limitations when using existing supplements due to dietary sensitivities. The product design is expected to be finalized shortly, with packaging and distribution strategies to follow in the coming months.

The company’s broader vision is to challenge what it calls outdated norms in pet nutrition and offer evidence-based solutions for modern challenges. “Our strategy is simple: make LeanPaws the go-to vet-recommended natural weight management supplement on the market,” the founders said in a statement.

Set to launch in early 2026, LeanPaws represents Omni’s most ambitious step yet into functional pet health products. With canine obesity showing no signs of decline, the company sees significant potential in a supplement that combines consumer appeal with veterinary endorsement. Owners interested in updates can already sign up to a waiting list, while Omni continues to refine its scientific and commercial plans ahead of market entry.